Prognostic Evaluation II

A new proposal of TNMH; the role of HLA and TNF B alleles as a prognostic, preventive and therapeutic factor in oncology

K Tsuji, K Ogoshi, T Shimura, M Hagihara

Bone marrow stromal cell defects underlying myeloid leukemias

I Blazsek, Ph Quittet, C Farabos, BK Triana, M Reynes, D Machover and JL Misset

Chemosensitivity of malignant gliomas in vitro prediction of efficacy of anticancer drugs

J Luttges, M Dietel, K Heuser, B Schafer,I Herzig, M Mehdorn

Immunohistochemical predictors for local control or prognosis of cervical cancer following radiation therapy

T Nakano, K Oka, N Ishikawa, S Morita

G-and F-actins as phenotypic markers for predictive oncology and chemoprevention of bladder cancer

GP Hemstreet, RE Hurst, JY Rao and RA Bonner

Correlation between expression of matrix proteinases and metastatic progression in gastric cancer

H Fujita, Y Yonemura, Y Endo, H Nose,K Tsuchihara, T Kawamura, K Miwa, I Miyazaki and T Sasaki

The numerical aberrations of chromosome 7 in human breast cancers

N Yoshimi, C Shibuya, Y Kashiki, M Suzui, T Tanaka, R Mori

Chromosome aberrations in rat liver induced in vivo by hepatocarcinogens

S Sawada, H Daimon, S Asakura, C Furihata

Expression of P-glycoprotein and outcome of chemotherapy in hepatocellular carcinoma

M Itsubo, T Ishikawa, G Toda

Influence of physiological concentration of progesterone on CD4+ - and CD8+ - activated lymphocytes with interleukin 2 and autologous plasma: difference between healthy donors and patients bearing malignant tumors

Y Kimoto, F-Z Tong, T Taguchi